NEW YORK--(BUSINESS WIRE)--The following statement is being issued by Levi & Korsinsky, LLP:
To: All Persons or Entities who purchased iKang Healthcare Group, Inc. (“iKang” or the “Company”) (NASDAQGS:KANG) stock prior to March 26, 2018.
You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of iKang to a consortium of entities led by CEO and Chairman Lee Ligang Zhang and Vice Chairman of the Board Boquan He. Under the terms of the transaction, iKang shareholders will receive US$41.20 per Class A or Class C common share and US$20.60 per American depositary share. Mr. Zhang and Mr. Boquan have agreed to tender their shares, representing approximately 25.6% of the Company’s outstanding shares and approximately 43.1% of total voting power of the outstanding shares. To learn more about the action and your rights, go to:
or contact Joseph E. Levi, Esq. either via email at email@example.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The investigation concerns whether the Board of iKang breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether the consortium is underpaying for iKang shares, thus unlawfully harming iKang shareholders.
Levi & Korsinsky is a national firm with offices in New York, Connecticut, California, and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.